Merck's Lipfendra wins FDA approval as the first oral PCSK9 inhibitor, and Canadian plan sponsors have reason to watch closely
The US Food and Drug Administration (FDA) approved Merck’s Lipfendra (enlicitide) on July 16, 2026. It’s the first oral drug of its kind to lower LDL cholesterol. For Canadian plan sponsors managing group benefits drug costs, the development is worth tracking closely.
Lipfendra works through a mechanism called PCSK9 inhibition. Until now, all approved drugs in this class were delivered by injection. Lipfendra is a once-daily pill — a meaningful shift in how this type of cholesterol treatment can be administered.
The drug is approved for adults with hypercholesterolemia, including a hereditary form of the condition called heterozygous familial hypercholesterolemia.
What the evidence base means for coverage
Lipfendra reduced LDL cholesterol by 56 percent compared to placebo in its Phase 3 trial, according to Merck’s July 16, 2026 press release. Merck also stated that cholesterol levels fell by 59 percent in a second trial focused on patients with a hereditary cholesterol condition.
One important caveat for plan sponsors: the approval is based on LDL reduction, not on hard cardiovascular outcomes. Whether Lipfendra reduces heart attacks, strokes, or cardiovascular death has not yet been established.
Private payers — and eventually Canadian insurers — will likely require that outcomes data before making broad formulary decisions. Plan sponsors reviewing cardiovascular drug coverage should factor that gap into any early monitoring discussions with their benefits consultants.
What this means for group benefits drug costs
Merck has priced Lipfendra at US$315 per month before discounts, roughly US$3,800 per year. That is below the list price of existing injectable PCSK9 inhibitors, which carry annual costs in the US$6,000-plus range, according to reporting by Fierce Pharma.
Oral administration may also improve adherence compared to injectables. That matters for plan sponsors. Poor adherence to cardiovascular medications drives higher downstream claims for hospitalisation, disability, and lost productivity.
Merck has stated it intends to submit Lipfendra to regulators worldwide. A Health Canada submission timeline has not been confirmed publicly.
Canadian benefits professionals can monitor high-cost drug formulary developments as new drugs move through regulatory pipelines. Managing drug formulary inclusion decisions proactively is increasingly important as novel therapies emerge.
Plan sponsors operating under administrative services only (ASO) structures should also review how specialty drug cost pooling is structured before a drug like this reaches Canadian formularies. High-cost drugs can create significant renewal pressure if pooling arrangements are not set up correctly in advance.
For organisations already tracking the impact of GLP-1 drugs on group benefits drug costs, Lipfendra’s approval is a reminder that the specialty drug pipeline remains active well beyond obesity medications.
Looking ahead
Canadian plan sponsors do not need to act right away, but formulary pressure builds fast once a novel drug gains traction. Sponsors who begin monitoring now and who review their cardiovascular drug coverage criteria will be better positioned when a Canadian decision arrives.
Here’s the US FDA’s official approval of Lipfendra.
